Ajay Sharma

Dr. Ajay Sharma is an esteemed Associate Professor at Chapman University's School of Pharmacy, where he has established himself as a leading authority in the field of ocular pharmacology. His expertise is particularly pronounced in areas such as dry eye, ocular surface diseases, and pharmacogenomics. Dr. Sharma's academic journey is marked by a Ph.D. in Pharmacology, followed by a prestigious postdoctoral fellowship at the University of Washington, where he honed his skills in gene therapy for ocular diseases and corneal healing. Throughout his career, Dr. Sharma has made significant contributions to the field of pharmacology, particularly in the realm of cardiovascular drug discovery. His teaching portfolio is extensive, having delivered pharmacology courses across various academic levels, thereby shaping the next generation of pharmacists and researchers. His dedication to education is matched by his prolific research output, with over 50 peer-reviewed articles to his name, alongside contributions to several book chapters. Dr. Sharma's research interests are diverse yet interconnected, focusing on anterior segment ocular diseases, ocular pharmacokinetics, and the complexities of ischemic myocardium. His work in these areas has not only advanced scientific understanding but also paved the way for innovative therapeutic approaches. In addition to his research and teaching responsibilities, Dr. Sharma is actively involved in the scientific community, serving as an editorial board member and interim reviewer for numerous esteemed scientific journals. His commitment to advancing the field of ocular pharmacology is evident in his ongoing research endeavors, which continue to explore the intricate mechanisms of ocular diseases and potential pharmacological interventions. Dr. Sharma's work is characterized by a deep understanding of the genetic and molecular underpinnings of ocular conditions, which he leverages to develop targeted therapies aimed at improving patient outcomes. Dr. Sharma's contributions to the field have not gone unnoticed, as he is frequently invited to speak at national and international conferences, where he shares his insights and findings with fellow researchers and practitioners. His work not only enhances the academic landscape but also holds promise for tangible improvements in clinical practice, particularly in the management of ocular and cardiovascular diseases.